TY - JOUR
T1 - Substance use disorders
T2 - Psychoneuroimmunological mechanisms and new targets for therapy
AU - Loftis, Jennifer M.
AU - Huckans, Marilyn
N1 - Funding Information:
This work was in part supported by NIDA/NIH grant DA018165 to the Methamphetamine Abuse Research Center (MARC) in Portland, Oregon. This material is the result of work supported with resources and the use of facilities at the Portland Veterans Affairs Medical Center and Oregon Health & Sciences University .
PY - 2013/8
Y1 - 2013/8
N2 - An estimated 76.4 million people worldwide meet criteria for alcohol use disorders, and 15.3 million meet criteria for drug use disorders. Given the high rates of addiction and the associated health, economic, and social costs, it is essential to develop a thorough understanding of the impact of substance abuse on mental and physical health outcomes and to identify new treatment approaches for substance use disorders (SUDs). Psychoneuroimmunology is a rapidly expanding, multidisciplinary area of research that may be of particular importance to addiction medicine, as its focus is on the dynamic and complex interactions among behavioral factors, the central nervous system, and the endocrine and immune systems (Ader, 2001). This review, therefore, focuses on: 1) the psychoneuroimmunologic effects of SUDs by substance type and use pattern, and 2) the current and future treatment strategies, including barriers that can impede successful recovery outcomes. Evidence-based psychosocial and pharmacotherapeutic treatments are reviewed. Psychological factors and central nervous system correlates that impact treatment adherence and response are discussed. Several novel therapeutic approaches that are currently under investigation are introduced; translational data from animal and human studies is presented, highlighting immunotherapy as a promising new direction for addiction medicine.
AB - An estimated 76.4 million people worldwide meet criteria for alcohol use disorders, and 15.3 million meet criteria for drug use disorders. Given the high rates of addiction and the associated health, economic, and social costs, it is essential to develop a thorough understanding of the impact of substance abuse on mental and physical health outcomes and to identify new treatment approaches for substance use disorders (SUDs). Psychoneuroimmunology is a rapidly expanding, multidisciplinary area of research that may be of particular importance to addiction medicine, as its focus is on the dynamic and complex interactions among behavioral factors, the central nervous system, and the endocrine and immune systems (Ader, 2001). This review, therefore, focuses on: 1) the psychoneuroimmunologic effects of SUDs by substance type and use pattern, and 2) the current and future treatment strategies, including barriers that can impede successful recovery outcomes. Evidence-based psychosocial and pharmacotherapeutic treatments are reviewed. Psychological factors and central nervous system correlates that impact treatment adherence and response are discussed. Several novel therapeutic approaches that are currently under investigation are introduced; translational data from animal and human studies is presented, highlighting immunotherapy as a promising new direction for addiction medicine.
KW - Addiction
KW - Drug discovery
KW - Inflammation
KW - Psychoneuroimmunology
KW - Substance use disorders
KW - Treatment strategies
UR - http://www.scopus.com/inward/record.url?scp=84879420504&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879420504&partnerID=8YFLogxK
U2 - 10.1016/j.pharmthera.2013.04.011
DO - 10.1016/j.pharmthera.2013.04.011
M3 - Review article
C2 - 23631821
AN - SCOPUS:84879420504
SN - 0163-7258
VL - 139
SP - 289
EP - 300
JO - Pharmacology and Therapeutics
JF - Pharmacology and Therapeutics
IS - 2
ER -